

RIG-I Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP1900a**Specification**

RIG-I Antibody (C-term) Blocking Peptide - Product InformationPrimary Accession [O95786](#)**RIG-I Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 23586**Other Names**

Probable ATP-dependent RNA helicase DDX58, DEAD box protein 58, RIG-I-like receptor 1, RLR-1, Retinoic acid-inducible gene 1 protein, RIG-1, Retinoic acid-inducible gene I protein, RIG-I, DDX58

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP1900a](/product/products/AP1900a) was selected from the C-term region of human RIG-I. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

RIG-I Antibody (C-term) Blocking Peptide - Protein Information**Name** RIGI ([HGNC:19102](#))**Synonyms** DDX58**Function**

Innate immune receptor that senses cytoplasmic viral nucleic acids and activates a downstream signaling cascade leading to the production of type I interferons and pro-inflammatory cytokines (PubMed: [15208624](http://www.uniprot.org/citations/15208624), PubMed: [15708988](http://www.uniprot.org/citations/15708988), PubMed: [16125763](http://www.uniprot.org/citations/16125763), PubMed: [16127453](http://www.uniprot.org/citations/16127453), PubMed: [16153868](http://www.uniprot.org/citations/16153868), PubMed: [17190814](http://www.uniprot.org/citations/17190814), PubMed: [18636086](http://www.uniprot.org/citations/18636086)),

PubMed:19122199, PubMed:19211564, PubMed:24366338, PubMed:28469175, PubMed:29117565, PubMed:31006531, PubMed:34935440, PubMed:35263596, PubMed:36793726). Forms a ribonucleoprotein complex with viral RNAs on which it homooligomerizes to form filaments (PubMed:15208624, PubMed:15708988). The homooligomerization allows the recruitment of RNF135 an E3 ubiquitin-protein ligase that activates and amplifies the RIG-I- mediated antiviral signaling in an RNA length-dependent manner through ubiquitination-dependent and -independent mechanisms (PubMed:28469175, PubMed:31006531). Upon activation, associates with mitochondria antiviral signaling protein (MAVS/IPS1) that activates the IKK-related kinases TBK1 and IKKε which in turn phosphorylate the interferon regulatory factors IRF3 and IRF7, activating transcription of antiviral immunological genes including the IFN-α and IFN-β interferons (PubMed:28469175, PubMed:31006531). Ligands include 5'- triphosphorylated ssRNAs and dsRNAs but also short dsRNAs (<1 kb in length) (PubMed:15208624, PubMed:15708988, PubMed:19576794, PubMed:19609254, PubMed:21742966). In addition to the 5'-triphosphate moiety, blunt-end base pairing at the 5'-end of the RNA is very essential (PubMed:15208624, PubMed:15708988, PubMed:19576794, PubMed:19609254, PubMed:21742966). Overhangs at the non- triphosphorylated end of the dsRNA RNA have no major impact on its activity (PubMed:15208624, PubMed:15708988, PubMed:19576794, PubMed:19609254, PubMed:21742966). A 3'overhang at the 5'triphosphate end decreases and any 5'overhang at the 5' triphosphate end abolishes its activity (PubMed:15208624, PubMed:15708988, PubMed:19576794, PubMed:19609254, PubMed:21742966). Detects both positive and negative strand RNA viruses including members of the families Paramyxoviridae: Human respiratory syncytial virus and measles virus (MeV), Rhabdoviridae: vesicular stomatitis virus (VSV), Orthomyxoviridae: influenza A and B virus, Flaviviridae: Japanese encephalitis virus (JEV), hepatitis C virus (HCV), dengue virus (DENV) and west Nile virus (WNV) (PubMed:21616437, PubMed:21884169). It also detects rotaviruses and reoviruses (PubMed:21616437, PubMed:21884169). Detects and

binds to SARS-CoV-2 RNAs which is inhibited by m6A RNA modifications (Ref.74). Also involved in antiviral signaling in response to viruses containing a dsDNA genome such as Epstein-Barr virus (EBV) (PubMed:19631370). Detects dsRNA produced from non-self dsDNA by RNA polymerase III, such as Epstein-Barr virus-encoded RNAs (EBERs). May play important roles in granulocyte production and differentiation, bacterial phagocytosis and in the regulation of cell migration.

Cellular Location

Cytoplasm. Cell projection, ruffle membrane. Cytoplasm, cytoskeleton. Cell junction, tight junction
Note=Colocalized with TRIM25 at cytoplasmic perinuclear bodies Associated with the actin cytoskeleton at membrane ruffles

Tissue Location

Present in vascular smooth cells (at protein level).

RIG-I Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

RIG-I Antibody (C-term) Blocking Peptide - Images

RIG-I Antibody (C-term) Blocking Peptide - Background

DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases which are implicated in a number of cellular processes involving RNA binding and alteration of RNA secondary structure. RIG-I contains RNA helicase-DEAD box protein motifs and a caspase recruitment domain (CARD). It is involved in viral double-stranded (ds) RNA recognition and the innate immune defense against viruses. Upon interaction with intracellular dsRNA produced during viral replication, RIG-I triggers a transduction cascade involving MAVS/IPS1, which results in the activation of NF-kappa-B, IRF3 and IRF7 and the induction of the expression of antiviral cytokines such as IFN-beta and RANTES (CCL5). This protein is essential for the production of interferons in response to RNA viruses including paramyxoviruses, influenza viruses, Japanese encephalitis virus and HCV.

RIG-I Antibody (C-term) Blocking Peptide - References

Li, K., et al., J. Biol. Chem. 280(17):16739-16747 (2005).Breiman, A., et al., J. Virol. 79(7):3969-3978 (2005).Cui, X.F., et al., Biochem. Cell Biol. 82(3):401-405 (2004).Imaizumi, T., et al., Life Sci. 75(10):1171-1180 (2004).Imaizumi, T., et al., Endothelium 11 (3-4), 169-173 (2004) ().